The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals after-the-fact rebates for two drugs in ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

Against the background described above, "betting big" on a topical treatment for plaque psoriasis make a lot of sense, ...

in patients with moderate to severe plaque psoriasis and scalp psoriasis. This trial highlighted the significant potential of guselkumab in treating psoriasis, which may boost the market. Additionally ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Study authors examined the use of artificial intelligence in machine learning models for the assessment of psoriasis severity, as well as identified future research needs.

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

Imuldosa, formerly known as DMB-3115, is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adult and pediatric patients 6 years of age ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...